
    
      This is a prospective, single-center and single-arm exploratory clinical study designed to
      evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of
      patients with BCLC stage B and C hepatocellular carcinoma.Treatment will continue until the
      death or intolerable toxicity or patients withdrawal of consent,and the target sample size is
      54 individuals.
    
  